1. Introduction
===============

For decade, cytomegalovirus (CMV) infection has been identified as a major risk factor of morbi-mortality after allogeneic stem cell transplantation (alloSCT) for hematologic malignancies.^\[[@R1],[@R2]\]^ This implied a careful policy for donor choice with regard to CMV serological status as well as a strict monitoring of CMV during transplant and early introduction of pre-emptive antiviral therapy to limit the risk of CMV disease. Despite these strategies, donor and/or recipient CMV seropositivity is still associated with an adverse prognosis. However, recent studies have reported a beneficial effect of early CMV reactivation after transplant with respect to relapse prevention, but this effect seems unclear regard to overall survival.^\[[@R3]--[@R6]\]^ In these studies dealing with various hematologic malignancies, this protective effect appeared to be more specific in acute myeloid leukemia (AML) patients and independent of graft versus host disease (GVHD). However, beside CMV, viral reactivations induced by the profound immunosuppression of alloSCT may also involve many other viruses including polyomavirus, Epstein--Barr virus or herpes viruses. In this study, we evaluated the impact of both viral reactivation and CMV serological status in a cohort of AML patients undergoing alloSCT in first complete remission (CR1).

2. Methods
==========

2.1. Study population
---------------------

Between 01/01/2000 and 12/31/2012, 727 AML patients (age 18--70) received intensive chemotherapy and 556 achieved a CR1.^\[[@R7],[@R8]\]^ Of them, 150 patients underwent alloSCT. Patients having received umbilical cord blood as stem cell source (n = 4) and sequential conditioning regimen (n = 10) were excluded leading to a sample of 136 patients for the analysis.

This study was approved by the ethic committee of Toulouse University Hospital (40-0713).

2.2. Transplant characteristics
-------------------------------

Conditioning regimen were classified according to a consensus definition of conditioning regimen intensity.^\[[@R9]\]^ Myeloablative conditioning (MAC) consisted of high-dose cyclophosphamide with total-body irradiation or busulfan. Reduced-intensity and non-myeloablative conditioning were grouped together under the reduced-intensity conditioning (RIC) term. RIC associated busulfan, fludarabine, and antithymocyte globulin or fludarabine and low total-body irradiation.

GVHD prevention consisted in a calcineurine inhibitor (ciclosporine A) alone or in association with either methotrexate (MTX) or mycophenolate mofetil (MMF).

2.3. Outcomes and definitions
-----------------------------

The primary endpoint was cumulative incidence of relapse.^\[[@R10]\]^ Secondary endpoints were overall survival (OS), disease-free survival (DFS), and non relapse mortality (NRM).^\[[@R11]\]^

The end of follow-up of our study was December 31, 2013.

AML risk groups were defined according to the Medical Research Council and the European LeukemiaNet classification.^\[[@R11],[@R12]\]^

Acute and chronic GVHD were diagnosed and graded according to standard consensus criteria.^\[[@R13],[@R14]\]^

2.4. Viral monitoring
---------------------

All patients underwent twice-weekly surveillance of CMV reactivation by pp65 antigenemia (≥1 pp65-antigene-positive cell per 2 slides with \>2.0 × 10^5^ white blood cells per slide) from 2000 to 2005 or real-time qPCR testing (2 consecutive positive PCR ≥ 500 copies/mL) thereafter, from the engraftment until 100 days after alloSCT. History of any other viral infection reported in the medical record and any positive biologic assay (by PCR) were taken into account in this study.

2.5. CMV pre-emptive therapy
----------------------------

Pre-emptive anti-CMV treatment consisted of intravenous ganciclovir (5 mg/kg twice a day) or oral valganciclovir (900 mg twice a day) for 14 days. In case of viral load decrease, antiviral therapy was continued on a maintenance dose for at least 14 days and until 2 consecutive monitoring was negative (5 mg/kg for IV ganciclovir and 450 mg twice a day for oral valganciclovir). Thereafter, antiviral treatment was pursued with either acyclovir or valacyclovir as herpes simplex virus type 1 and 2, or varicella--zoster virus prophylaxis.

2.6. Statistical analyses
-------------------------

Before doing any analysis, we assessed the power of the study: 41 relapses provide a power \>80% to detect a hazard ratio (HR) of relapse \<0.5 (for CMV −/+, CMV +/+, CMV +/− vs CMV−/− or for any viral reactivation versus no viral reactivation) with 2-sided type 1 error rate of 5% (α = 0.05) for the comparison of 2 exponential survival distributions.^\[[@R15]\]^

Statistical analysis was performed on STATA statistical software, release 11.2 (STATA Corp., College Station, TX).

We described patients' characteristics using number and frequency for categorical data, median and range (minimum--maximum) for continuous data.

Comparisons of patients' characteristics (for CMV −/+, CMV +/+, CMV +/− vs CMV−/−) were performed using the χ^2^-test (or Fisher\'s exact test in case of small expected numbers) for categorical variables and Student\'s *t*-test (or Mann--Whitney\'s test when distribution departed from normality or when homoscedasticity was rejected) for continuous variables.

Survival analyses were then conducted. Cumulative incidence functions (CIF) and Gray\'s test were used for relapse and NRM, since events of relapse and NRM were treated as competing events. For OS and DFS, Kaplan--Meier survival curves were drawn and differences in survival functions were tested using the Log-Rank test. OS was defined as the time from the first complete remission after intensive induction chemotherapy to death from any cause or last follow-up. The last time of follow-up of our study was December 31, 2013. DFS was defined as the time from first complete remission after intensive therapy to relapse or death without relapse. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were assessed using a standard Cox model, for OS and DFS, and a proportional subdistribution hazard model which is an extension of the Cox model to the situation of competing risks,^\[[@R16]\]^ for the cumulative incidence of relapse (multivariate analysis was not conducted for NRM because of small sample of NRM \[n = 21\]). Variables initially introduced in multivariate analyses were all variables associated with relapse, OS or DFS in univariate analyses with a *P*-value \<0.20. Variables assessed in univariate analyses were potential confounding factors (patient characteristics at diagnosis such as cytogenetic and molecular abnormalities and patient, donor and transplant characteristics at allogeneic SCT and after transplant). A backward analysis was then applied until only variables significantly and independently associated with relapse, OS or DFS (*P*-value \<0.05) remained. The proportional-hazard assumption was tested for each covariate of the Cox model by the "log--log" plot method curves and was always met. When the linearity hypothesis was not respected, continuous variables were transformed into ordered data. Interactions between independent covariates were tested in final models and none were significant. Viral reactivation and GVHD were evaluated as time-dependent covariates. For the assessment of the potential protective effect of CMV serological status, we replaced the viral reactivation by CMV serological status in final multivariate models. Indeed CMV serological status and viral reactivation were known to be involved in a mediation relationship (i.e., CMV serological status promotes viral reactivation). Because the effect of CMV serological status is included in viral reactivation, the effect of viral reactivation and CMV serological status cannot be assessed simultaneously in the same model.

All reported *P*-values were 2-sided and the significance threshold was \<0.05.

3. Results
==========

At time of transplant, donor and recipient (D/R) CMV serostatus were as follows: 46 D/R −/− (CMV-- group), and 90 D/R +/−, D/R+/+, or D/R −/+ (CMV+ group). Except for age, stem cell source, and GVHD prophylaxis, both clinical characteristics and GVHD incidence were similar between the 2 groups (Table [1](#T1){ref-type="table"}).

###### 

Patient, donor, and transplant characteristics according to cytomegalovirus serostatus.

![](md-95-e5356-g001)

At least 1 viral reactivation including CMV reactivation were recorded in 76 (56%) patients, 33% in the CMV-- group and 68% in the CMV+ group (*P* \< 0.01) (Table [2](#T2){ref-type="table"}). There were more CMV (53.3% vs 2.2%; *P* \< 0.01) and less EBV reactivations (4.4% vs 15.2%; *P* = 0.044) in the CMV+ group compared with the CMV-- group. Among the recipients of RIC, median time to CMV infection and viral reactivations were 35 (Inter-Quartile Range: 21--53) and 44 (24--63) days respectively, compared with 39 (26--55; *P* = 0.47) and 48 (33--91; *P* = 0.15) days among the MAC recipients.

###### 

Viral characteristics according to cytomegalovirus serological status (n\[%\]).
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With a median follow-up of 5.6 years, 41 relapses (30%) and 57 deaths (42%) were recorded.

The cumulative incidence of relapse (CIR) at 10 years was 15% (95% CI 7--23) in the group of patients who experienced viral reactivations compared with 54% (95% CI 41--70) in the group of patients without viral reactivation (*P* \< 0.01) (Fig. [1](#F1){ref-type="fig"}A). Ten year-CIR was also significantly lower in the CMV+ group (26%, 95% CI 18--38) compared with the CMV-- group (45%, 95% CI 28--58) (*P* = 0.03) (Fig. [2](#F2){ref-type="fig"}A).

![Relapse and survival stratified by viral reactivation. (A) Cumulative incidence of relapse (*P* \< 0.01), (B) nonrelapse mortality (*P* = 0.02), (C) disease-free survival (*P* = 0.04), and (D) overall survival (*P* = 0.10).](md-95-e5356-g003){#F1}

![Relapse and survival stratified by Cytomegalovirus serological status. (A) Cumulative incidence of relapse (*P* = 0.03), (B) nonrelapse mortality (*P* = 0.68), (C) disease-free survival (*P* = 0.02), and (D) overall survival (*P* = 0.02). CMV indicates cytomegalovirus.](md-95-e5356-g004){#F2}

In univariate analysis, viral reactivations and CMV+ serological status were associated with a significant reduced risk of relapse as well as chronic GVHD but not ELN classification, type of donor, conditioning regimen, stem cell source, or acute GVHD (data not shown). To assess the impact of both viral reactivations and CMV serostatus, which are involved in a mediation relationship (i.e., CMV serostatus promotes viral reactivation), 2 multivariate models were built (including viral reactivation for the first and CMV serostatus for the second). In these multivariate models, viral reactivations and CMV+ serostatus were still significantly associated with a reduced risk of relapse (Table [3](#T3){ref-type="table"}).

###### 

Multivariable analysis of the impact of viral reactivations and cytomegalovirus serological status on relapse, overall survival, and disease-free survival.
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In the group of patients who experienced viral reactivations, 10 year-NRM was 24% (95% CI 14--32) compared with 7% (95% CI 3--19) in the group of patients without viral reactivation (*P* = 0.02) (Fig. [1](#F1){ref-type="fig"}B). Ten year-NRM was not significantly different between CMV+ (15%, 95% CI 9--25) and CMV-- group (18%, 95% CI 8--30) (*P* = 0.68) (Fig. [2](#F2){ref-type="fig"}B). However, more patients died following AML relapse in the CMV-- group (37%, 95% CI 23--52) compared with the CMV+ group (19%, 95% CI 11--29) (*P* = 0.02). There was no difference between both groups, regarding other causes of death (Table [4](#T4){ref-type="table"}).

###### 

Causes of death.
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In the group of patients who experienced viral reactivations, 10 year-DFS was 63% (95% CI 51--73) compared with 35% (95% CI 21--50) in the group of patients without reactivation (*P* = 0.04) (Fig. [1](#F1){ref-type="fig"}C). Ten year-DFS was also significantly better in the CMV+ group (57%, 95% CI 45--68) compared with the CMV-- group (39%, 95% CI 24--53) (*P* = 0.02) (Fig. [2](#F2){ref-type="fig"}C). In multivariate models (Table [3](#T3){ref-type="table"}), viral reactivations and CMV+ serostatus were associated with a significantly better DFS.

In the group of patients who experienced viral reactivations, 10 year-OS was 63% (95% CI 49--74) compared with 41% (95% CI 27--55) in the group of patients without reactivation (*P* = 0.10) (Fig. [1](#F1){ref-type="fig"}D). Ten year-OS was also significantly better in the CMV+ group (59%, 95% CI 44--71) compared with the CMV-- group (41%, 95% CI 27--55) (*P* = 0.02) (Fig. [2](#F2){ref-type="fig"}D). In multivariate models, viral reactivations and CMV+ serostatus were still significantly associated with a reduced risk of death (Table [3](#T3){ref-type="table"}). Acute grade III-IV GVHD was significantly associated with poorer OS (adjusted HR 3.91; 95%CI 1.83--8.33; *P* \< 0.01).

4. Discussion
=============

Our study shows that, in AML patients allografted in first complete response, not only CMV serostatus but also viral reactivations as a whole have a clear impact on relapse incidence and survival independently of conditioning regimen, GVHD or stem-cell source. This finding is in accordance with other studies, although some of them failed to demonstrate an impact on survival.^\[[@R3],[@R4],[@R6]\]^ The mechanisms by which viral reactivations and relapse prevention could be linked remain unclear. The observation of such an effect particularly in AML as compared to other hematological malignancies is also intriguing. Elucidating which immune cell subpopulation is key to control residual disease will be crucial to rationally design immunotherapy against AML. Natural killer, CD8 and gamma/delta T cells have been shown to be stimulated by CMV reactivation and could cross-react with both viruses and leukemic cells.^\[[@R17]\]^ Moreover, a direct CMV\'s cytotoxic effect had recently been shown against blast cells, inducing apoptosis.^\[[@R18]\]^ However, viral reactivations are still associated with an increased risk of NRM and thus, choosing a donor according to CMV serostatus has now become a dilemma. Larger prospective studies in well-defined AML populations with respect to disease status, minimal residual disease, conditioning regimen, GVHD prophylaxis, and antiviral therapy are needed to clearly determine the clinical application of these finding.
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